Kopran Ltd. (KOPRAN) Share Price Rises 8.83% as Stock Traded Higher Today
- September 3, 2026
- Posted by: Harsh Piplani
- Category: News
Kopran Ltd. Share Price moved higher today, with the stock last traded at Rs 256.35, up 8.83% from the previous close of Rs 235.55. The company’s market capitalisation stood at Rs 1,137.37 Cr, placing the move in the context of a small-cap Healthcare name that is drawing fresh attention in the Indian Stock Market. According to latest Univest data, the rise is meaningful on a same-day basis, but the available market record does not establish a company-specific catalyst.
For readers tracking Kopran Ltd. Share Price Today, the move reflects a broad improvement in price action rather than a disclosed event trigger. The stock opened at Rs 234.8, touched a high of Rs 266 and a low of Rs 233.6, while turnover stood at Rs 11.94 Cr. In Univest coverage, this makes Kopran Ltd. Stock News relevant for investors who want to understand what the numbers show, how the valuation looks, and whether the current move is being backed by business fundamentals.
Kopran Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 256.35 |
| Previous Close | Rs 235.55 |
| Today's Move | Rs 20.8 (+8.83%) |
| Open | Rs 234.8 |
| High | Rs 266 |
| Low | Rs 233.6 |
| Turnover | Rs 11.94 crore |
| Market Capitalisation | Rs 1,137.37 crore |
| Market Cap Category | Small Cap |
Kopran Ltd. (KOPRAN) rose to Rs 256.35 from the previous close of Rs 235.55, a move of Rs 20.8 or 8.83%. The stock opened at Rs 234.8, reached a high of Rs 266, recorded a low of Rs 233.6.
Kopran Ltd. Share Price Today is being shaped by a clear intraday rise. The counter moved from a previous close of Rs 235.55 to Rs 256.35, adding Rs 20.8 or 8.83% during trade. It opened near the prior settlement at Rs 234.8, tested Rs 266 on the upside and Rs 233.6 on the downside, showing that buyers remained active through the morning. Turnover of Rs 11.94 Cr indicates noticeable participation, but latest Univest figures confirm only the price event, not a company-specific explanation. For stock news readers, this is the key fact: Kopran Ltd. Share Price is trading stronger today without an announced catalyst in the market record.
Kopran Ltd. (KOPRAN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,137.37 crore |
| P/E Ratio | 45.52x |
| P/B Ratio | 2.12x |
| ROE | 4.92% |
| ROCE | 6.65% |
| EPS | Rs 5.17 |
| Book Value Per Share | Rs 110.92 |
| Dividend Yield | 1.27% |
Kopran Ltd. (KOPRAN) fundamental metrics show P/E 45.52x, P/B 2.12x, ROE 4.92%, ROCE 6.65%. These figures provide context only and are not a buy or sell signal.
Kopran Ltd. has a market capitalisation of Rs 1137.37 crore and falls in the Small Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 45.52x, P/B at 2.12x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 4.92% and ROCE of 6.65%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 5.17, book value per share of Rs 110.92, dividend yield of 1.27%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.72x, median ROE of 11.69%, median ROCE of 13.24%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 45.52x |
| Benchmark Median P/E | 32.72x |
| Benchmark Average P/E | 49.15x |
| Benchmark P/E Range | 3.34x to 693.7x |
| Company P/B Ratio | 2.12x |
| Benchmark Median P/B | 3.05x |
| Company ROE | 4.92% |
| Benchmark Median ROE | 11.69% |
| Company ROCE | 6.65% |
| Benchmark Median ROCE | 13.24% |
| Company Market Capitalisation | Rs 1,137.37 crore |
| Benchmark Median Market Cap | Rs 704.59 crore |
Kopran Ltd. (KOPRAN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Kopran Ltd. (KOPRAN) has a P/E ratio of 45.52x, which is above the benchmark median of 32.72x, a difference of +39.12%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Kopran Ltd. (KOPRAN) has a ROE of 4.92%, which is below the benchmark median of 11.69%, a difference of -57.91%. Kopran Ltd. (KOPRAN) has a ROCE of 6.65%, which is below the benchmark median of 13.24%, a difference of -49.77%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,41,957.5 | 36.54 | 5.11 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,47,576 | 84.64 | 14.02 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,89,233.01 | 86.76 | 21.08 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,11,670.55 | 24.74 | 4.14 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,10,272.68 | 32.72 | 3.14 | 11.83 | 16 |
Kopran Ltd. (KOPRAN) has a P/E ratio of 45.52x compared with the displayed peer median of 36.54x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 4.92% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 6.65% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Kopran Ltd. (KOPRAN) has a market capitalisation of Rs 1,137.37 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Kopran Ltd.
- Kopran Ltd. Share Price is up 8.83% today, making it one of the notable Stocks Rising Today in the Healthcare space.
- The stock traded between Rs 233.6 and Rs 266, showing active price action during the current Share Market Today session.
- Kopran Ltd. Fundamental Analysis shows a P/E of 45.52, P/B of 2.12, ROE of 4.92% and ROCE of 6.65%.
- The company’s Rs 1,137.37 Cr market cap keeps it in the small-cap bracket, which often draws attention in Market Movers discussions.
- Sector comparison shows Kopran trading at a valuation above the industry median P/E, but with weaker profitability ratios than many peers.
About Kopran Ltd.
Kopran Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. The company’s market position is best understood as a smaller listed pharma name rather than one of the sector leaders, and its numbers reflect that profile. Investors tracking Kopran Ltd. Share Price on Univest generally look at how the company fits into the broader Indian Stock Market for pharma and healthcare names.
From a business perspective, the company belongs to a sector where growth, regulation, pricing power and operating efficiency matter heavily. That makes Kopran Ltd. Stock Analysis useful for investors who compare valuation with returns on equity and capital employed. The latest Univest figures show market cap, P/E, P/B, EPS, book value and dividend yield in one place, helping readers understand the company’s financial position without mixing it with unrelated market noise. Kopran Ltd. Company News will remain relevant when the market looks for whether earnings quality can catch up with valuation.
Frequently Asked Questions
Why is Kopran Ltd. Share Price rising today?
Ans. Kopran Ltd. Share Price rose 8.83% to Rs 256.35, but the market record does not establish a company-specific catalyst. The move is visible in today’s price action and turnover of Rs 11.94 Cr.
What is Kopran Ltd. Share Price Today?
Ans. Kopran Ltd. Share Price Today is Rs 256.35. It is higher by Rs 20.8 compared with the previous close of Rs 235.55, showing a clear same-day gain during trade.
What is Kopran Ltd. market capitalisation?
Ans. Kopran Ltd. market capitalisation stands at Rs 1,137.37 Cr. That places the company above the industry median market cap in Pharmaceuticals & Drugs, while remaining far below large-cap pharma peers.
Is Kopran Ltd. expensive compared with peers?
Ans. Kopran’s P/E of 45.52 is above the industry median of 32.72 and below the average of 49.15. Its P/B of 2.12 is lower than the benchmark median, which gives mixed valuation context.
What do Kopran Ltd. earnings ratios show?
Ans. Kopran Ltd. reports ROE of 4.92% and ROCE of 6.65%. Both are below the sector medians, indicating that returns on equity and capital employed are modest versus the Healthcare benchmark.
What is Kopran Ltd. EPS and book value?
Ans. Kopran Ltd. EPS is Rs 5.17 and book value is Rs 110.92. EPS shows earnings attributable to each share, while book value reflects accounting net worth per share.
Does Kopran Ltd. pay a dividend?
Ans. Kopran Ltd. has a dividend yield of 1.27%. Dividend yield is historical and current payout-related data, so it adds income context but does not guarantee future distributions or payout levels.
How does Kopran Ltd. compare with pharma peers?
Ans. Compared with Sun Pharma, Cipla and Zydus Lifesciences, Kopran is much smaller in market cap. Its valuation is also not the cheapest, while profitability ratios remain below several listed peers.
Track Kopran Ltd. Share Price on Univest
Use Kopran Ltd. (KOPRAN) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Investors can track Kopran Ltd. Share Price Live on Univest for price updates, market cap, P/E ratio, P/B ratio, EPS, book value, dividend yield, sector analysis and peer comparison. Univest also brings together Kopran Ltd. Latest News and Kopran Ltd. Share Price Update in one place for faster reading.
For those researching Kopran Ltd. NSE activity, Univest offers a clean view of the stock’s movement, fundamental ratios and industry benchmark context. If you are scanning Stocks in News or Top Gainers Today, the platform helps you compare Kopran Ltd. Stock Performance with other Healthcare names using the same latest market lens.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
